Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 2, 2010
Effect of cetuximab treatment in squamous cell carcinomasMarika Nestor
Journal of Molecular Recognition : JMR|April 29, 2008
Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassayMarika Nestor, Karl Andersson, Hans Lundqvist
Pharmaceutical Research|March 15, 2003
Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processingErika Bohl Kullberg, Marika Nestor, Lars Gedda
Nuclear Medicine and Biology|January 12, 2011
Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomasMarika Nestor, Magnus Sundström, Matti Anniko, et al.
Nuclear Medicine and Biology|December 3, 2013
Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6Jonas Stenberg, Diana Spiegelberg, Hampus Karlsson, et al.
International Journal of Oncology|October 23, 2019
The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cellsSara Lundsten, Diana Spiegelberg, Bo Stenerlöw, et al.
Biotechnology and Applied Biochemistry|April 17, 2013
Selection and in vitro characterization of human CD44v6-binding antibody fragmentsJohan Nilvebrant, Gamze Kuku, Hanna Björkelund, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2020
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenograftsSara Lundsten, Diana Spiegelberg, Nakul R Raval, et al.
Nuclear Medicine and Biology|December 26, 2015
A real-time in vitro assay as a potential predictor of in vivo tumor imaging propertiesDiana Spiegelberg, Jonas Stenberg, Anna-Karin Haylock, et al.
Pageof 7